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The aimof this studywas to assess the prevalence ofHPV infection and determinants of abnormal cytology inHIV-positive patients.
In a cross-sectional study, patients of both sexes, asymptomatic for HPV, underwent anorectal (men)/cervical (women) and oral
swabs. Cytology and HPV-PCR detection/genotyping (high- and low-risk genotypes, HR-LR/HPV) were performed. A total of
20% of the 277 enrolled patients showed oral HPV, with no atypical cytology; in men, anal HPV prevalence was 81% with 64% HR
genotypes. In women, cervical HPV prevalence was 58% with 37%HR-HPV.Themost frequent genotypes were HPV-16 and HPV-
18; 37% of men and 20% of women harbored multiple genotypes. Also, 47% of men showed anal squamous intraepithelial lesions
(SILs); 6% had high- and 35% low-grade SILs (HSILs/LSILs); 5% had atypical squamous cells of undetermined significance (ASC-
US). HR-HPV was independently associated with anal-SIL in men (𝑃 = 0.039). Moreover, 37% of women showed cervical SIL: 14
ASC-US, 15 LSILs, 4 HSILs, and 1 in situ cancer. The presence of both LR and HR-HPV in women was independently associated
with SIL (𝑃 = 0.003 and 𝑃 = 0.0001). HR-HPV and atypical cytology were frequently identified in our cohort. HPV screening
should be mandatory in HIV-infected subjects, and vaccine programs for HPV-negative patients should be implemented.
1. Introduction
Human papillomavirus (HPV) is one of the most common
sexually transmitted pathogens, responsible of several differ-
ent diseases ranging from benign common warts to invasive
carcinoma at a variety of anatomical sites, including the
cervix, vulva, vagina, penis, anus, and oropharynx [1].
While the immune system eliminates over time most
HPV infections in immunocompetents individuals, HPV
infections tend to persist in immunodeficient ones, such as
HIV-positive subjects, probably due to the inability to control
the expression and replication of HPV by HIV-compromised
immune system [2]. Persistent infections with oncogenic
HPV genotypes are causally related to the development of
high-grade intraepithelial lesions and invasive carcinoma.
Many studies have shown a higher incidence of HPV-
related cervical cancer [3] in HIV-positive women compared
to general population, and in 1993, cervical cancer was
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included in the list of AIDS defining conditions [4]. Later,
attentionwas paid on anal cancer and its increasing incidence
inHIV-positive patients, especially inmenwho have sex with
men (MSM), when compared with HIV-negative controls
[5]. Furthermore, the risk of other HPV-associated cancers,
like oropharyngeal, has been demonstrated to be increased
among HIV-infected individuals [6].
The effect of highly active antiretroviral therapy
(HAART) on the incidence of HPV-associated infection and
related neoplasia is controversial. Several studies have
indicated that the incidence of anal cancer but not cervical
cancer is increased with HAART [7, 8]. At the same time,
HAART has not been shown to substantially reduce
progression to high-grade cervical intraepithelial neoplasia
(CIN) or anal intraepithelial neoplasia (AIN) in HPV-HIV-
coinfected individuals [9]. To date, no studies have analyzed
HPV infection at oral and genital sites and related dysplasia
in the context of effective HAART.
Epidemiological studies on local (Italian) prevalence of
HPV cervical infection in HIV-negative women published
in recent years showed HPV prevalence ranging from 8.8%
[10] to 38% [11] depending on the population examined. In
Northern Italy (region in which the present study is done),
the prevalence of cervical cancer screening is higher than in
other regions, covering 79.5% of women versus 70.9% [12].
Few studies have investigated anal HPV prevalence in HIV-
negative population in Italy; a recent study conducted on
HIV-negative MSM individuals, attending sexually transmit-
ted infections (STIs) clinic in Rome showed a prevalence of
anal HPV infection of around 74% [13].
Given these considerations, the aims of our study were to
assess the prevalence, genotype diversity, and determinants
of HPV infection at different mucosal sites (oral, cervical,
and anal) in a cohort of HIV-positive men and women
asymptomatic for HPV. Furthermore, we wanted to assess
the prevalence of atypical cytology at different sites and
to identify any demographic and clinical factors associated
with the development of intraepithelial lesions, considered
precancerous lesions.
2. Methods
2.1. Study Population. We performed a cross-sectional study
in a cohort of HIV-positive men and women followed at the
Clinic of Infectious Diseases, Department of Health Sciences,
San Paolo Hospital, Milan, between January 2009 and Febru-
ary 2011. Inclusion criteria were HIV positive, age ≥18 years,
routinely followed by the clinic, asymptomatic for genital
diseases, and signed the informed consent to participate the
study. Exclusion criteria were history of anal/cervical cancer,
ongoing genital signs and symptoms (discharge, discomfort,
or ulceration), and refusal to sign the informed consent.
Patients were asked to complete an anonymous struc-
tured questionnaire on sexual behavior. The questionnaire
was not validated; 14 self-reported questions were asked
on the number of partners, genital intercourse, oral inter-
course, and history of sexually transmitted diseases (STDs)
(attached as supplementary document available online at doi:
http://dx.doi.org/10.1155/2013/915169).
2.2. Surgical, Gynecological, and Dental Visits. During the
gynecological and surgical visits, cervical specimens
(women) and anal specimens (men) were collected to analyze
cytology and detect HPV. Oral specimens were obtained
during the dentistry visit for both sexes for the same analyses.
In particular, the oral sample was obtained by scraping
the walls of the oropharyngeal cavity and gums using a
dermatologic curette (a scalpel with blade ring and a diameter
of 7mm) with tangential movements at about 30 degrees on
the mucosal. Then with the help of a Heidemann spatula,
the material collected was smeared on a slide for citologyc
analysis. Another sample obtained in the same way was
collected in liquid-based cytology medium (PreservCyt-
Hologic) for HPV detection and genotyping.
2.3. Cytology. Anal, cervical, and oral cytology samples were
collected using a Dacron swab to perform a pap smear. The
cytology was read by expert cytopathologists, with expertise
in oral cytology and classified according to the 2001 Bethesda
System terminology as negative, atypical squamous cells
of undetermined significance (ASC-US), atypical squamous
cells that cannot exclude high-grade SILs (ASC-H), low-
grade SILs (LSILs), high-grade SILs (HSILs), or carcinoma
[14]. Unsatisfactory oral, cervical, or anal cytology results
due to insufficient cellularity were excluded from cytological
classification.
2.4. HPVDetection andGenotyping. Specimens from the cer-
vical, oral, and anal mucosae were collected in liquid-based
cytology medium (PreservCyt-Hologic). Total DNA was
extracted using a commercial kit (QIAamp DNA Blood Mini
KIT, Qiagen). HPV DNA was detected with PCR using both
the L1 consensus primers MY09/MY11 [15] and the E6/E7
consensus primers PU-1M/PU-2R [16]. Viral genotyping was
performed using a direct sequencing kit (BD Terminator Kit
v 1.1, Applied Biosystems, Life Technologies) on an auto-
mated capillary electrophoresis sequencer (ABI3130, Applied
Biosystems, Life Technologies). The sequences obtained
were blasted against the NCBI nucleotide DNA database
using the Basic Local Alignment Search Tool (BLAST:
http://blast.ncbi.nlm.nih.gov/) to identify the viral genotype.
The oncogenic risk of the different viral genotypes was
defined according to the epidemiologic classification by
Mun˜oz et al. [17].
2.5. Statistical Analyses. Demographic and immunovirologi-
cal characteristics of the population were summarized using
absolute numbers and percentages for categorical variables
and medians and interquartile ranges (IQRs) for continuous
variables.
Categorical and continuous parameters were compared
between HPV-negative and HPV-positive patients of the
entire study population using Pearson’s chi-square test and
the Mann-Whitney test.
Two univariate and multivariate logistic regression anal-
yses were performed to explore factors associated with anal
(model 1) and cervical (model 2) dysplasia in men and
women, respectively. The following variables were included
in the model: age, exposure categories for HIV infection
Journal of Sexually Transmitted Diseases 3
(MSM versus noMSM and heterosexual women versus other
exposure categories), CDC stage C (according to CDC 1993
revised HIV classification of Center of Diseases and Control
of Atlanta; the system is based on 3 ranges of CD4 counts
and 3 clinical categories; C category includes all the AIDS
defining diseases) [4], ongoing HAART (yes versus no),
CD4+ T-cell Nadir count, and presence of HPV (LR and/or
HR versusnegative).
The analyses were performed using SPSS software (ver-
sion 18.0).
3. Results
3.1. Patient Characteristics. A total of 277 HIV-positive
patients were enrolled, and 97 (35.0%) were females. Female
prevalence of the study population is consistent with the
gender distribution in our clinic, with around 2/3 of patients
that weremales and 1/3 females, according to Italian data [18].
Demographic variables of the study population were similar
to those of all patients attending our clinic (data not shown).
The median age was 42 years (interquartile range-IQR: 35–
47). Sexual transmission was the most frequent route of
infection for both men (136/180 infected by homosexual and
29 by heterosexual intercourse) and women (69/97 infected
by heterosexual intercourse), as self-declared by the patients
during the first visit at the clinic and reported in the medical
history charts. Only 47 patients (17%) were in CDC group C;
222 (80.1%) were on HAART. Women had a longer duration
of documented HIV infection (median, IQR: 143, 55–210
versus 52, 24–411 months; 𝑃 = 0.0001), lower CD4 counts
at Nadir (median, IQR: 205 cells/mmc, 120–288 versus 273
cells/mmc, 163–397; 𝑃 = 0.003), and a longer duration
of HAART (median, IQR: 70, 33–152 versus 44, 22–130.5
months; 𝑃 = 0.05) compared with men. Demographic char-
acteristic of the study population according to HPV infection
status are shown in Table 1. A total of 117 (65.0%) men and
36 (37.1%) women completed the questionnaire on sexual
behavior, and 60% reported a positive history of STDs. Men
declared more than 25 sexual partners lifelong (61/117 versus
10/36; 𝑃 = 0.01) and anal intercourse (98/117 versus 14/36;
𝑃 < 0.0001) more frequently than women; oral intercourse
was reported by 87% of patients (see Table 2). A total of 44%
of the 277 enrolled patients did not complete the survey.
3.2. Prevalence of HPV at Anal, Cervical, and Oral Sites.
Each subject underwent a surgical (men) or gynecological
(women) visit; 201 patients (72%) underwent also a dental
visit (61 women and 140 men). The subjects were analyzed
for both HPV infection and abnormal cytology at genital and
oral sites.
A total of 40 (20%) tested individuals harbored HPV
infection at the oral site, and 18 (9.0%) had HR-HPV
genotypes. The overall prevalence of anal HPV in men was
81% (145/180 men), and HR-HPV was detected in 114/145
of them (78.6%). Cervical HPV was detected in 56 (58%)
of the 97 tested women, and 36/56 (64.3%) harbored HR-
HPV. Globally, HPV was detected at genital sites (cervical
in women and anal in men) in 201 individuals (72.6% of the
cohort), and 150/201 (74.6%) harbored HR types.
Table 1: Demographic characteristics of the study population
according to HPV infection status.
Characteristics HPV negative(76)
HPV positive
(201) 𝑃
Age∗ 42.5 (38–49) 41 (35–47) 0.119
Male∘ 35 (46%) 145 (72%) 0.0001
Exposure categories∘ 0.0001
MSM 17 (22%) 117 (58%)
Heterosexual 35 (46%) 62 (31%)
IDUs 23 (31%) 22 (10%)
Vertical 1 (1%) 0
CDC C∘ 18 (24%) 29 (14%) 0.067
HIV duration (mths)∗ 120 (39–181) 68 (29–169) 0.028
CD4+ T cells/mmc∗ 462 (346–636) 480 (357–665) 0.710
Nadir CD4+ T cells/mmc∗ 209 (139–287) 271 (157–392) 0.006
Log10 HIV RNA cp/mL
∗ 1.59 (1.59–1.79) 1.77 (1.59–3.25) 0.002
HAART∘ 63 (83%) 159 (79%) 0.480
HAART duration (mths)∗ 60 (40–133) 44 (22–123) 0.081
Dysplasia∘ 18 (23.7%) 99 (49.2%) 0.0001
∘Data are presented as the number (percentage). ∗Data are presented as the
median (IQR).
Exposure categories for HIV infection: MSM: men who have sex with men;
IDUs: injection drug users; CDC C: AIDS classification according to Atlanta
CDC 1993; HAART: highly active antiretroviral therapy.
Table 2: Data from sexual behavior questionnaires according to
gender and to HPV infection status.
Questionnaire HPV negative HPV positive 𝑃
Males (𝑛 = 117) (𝑛 = 28) (𝑛 = 89)
STDs∘ (𝑛 = 73, 62%) 𝑛 = 15 (53%) 𝑛 = 58 (65%) 0.26
>25 partners∘
(𝑛 = 61, 52%) 𝑛 = 7 (25%) 𝑛 = 54 (61%) 0.001
Anal intercourse∘
(𝑛 = 98, 83%) 𝑛 = 17 (60%) 𝑛 = 81 (91%) 0.0001
Oral intercourse∘
(𝑛 = 105, 89%) 𝑛 = 21 (75%) 𝑛 = 84 (94%) 0.0032
Females (𝑛 = 36) (𝑛 = 10) (𝑛 = 26)
STDs∘ (𝑛 = 19, 52%) 𝑛 = 2 (20%) 𝑛 = 17 (65%) 0.014
>25 partners∘
(𝑛 = 10, 27%) 𝑛 = 2 (20%) 𝑛 = 8 (31%) 0.51
Anal intercourse∘
(𝑛 = 14, 38%) 𝑛 = 3 (30%) 𝑛 = 11 (42%) 0.49
Oral intercourse∘
(𝑛 = 28, 77%) 𝑛 = 8 (80%) 𝑛 = 20 (77%) 0.84
STDs: sexually transmitted diseases.
A total of 78/201 subjects (38.8%) tested at both genital
and oral sites showed concordant HPV serostatus (HPV
positive in 32 cases and HPV negative in 46 cases); positivity
at only the oral site was found in 7 cases (3.5%), andHPVwas
only detected at genital sites in 116 cases (57.7%).
Overall, the subjects harboring HPV at any site were
more frequently men (men represented 72% of HPV-positive
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Figure 1: Prevalence of different HPV genotypes at the anal site (a), cervical site (b), and oral site (c). (a) The most frequent HPV genotypes
are listed on the abscissa. Genotypes 6 and 11 are low risk, and other LR indicates other low-risk genotypes. Genotypes 16, 18, 31, 33, 35, 53, 58,
and 66 are high risk, and other HR indicates other high-risk genotypes. The percentage indicates the prevalence of each genotype within the
total HPV genotypes in the HPV-positive population. (b) The most frequent HPV genotypes are listed on the abscissa. Genotypes 6 and 11
are low risk, and other LR indicates other low-risk genotypes. Genotypes 16, 18, 31, 33, 35, 52, 53, and 58 are high risk, and other HR indicates
other high-risk genotypes. The percentage indicates the prevalence of each genotype within the total HPV genotypes in the HPV-positive
population. (c) The most frequent HPV genotypes are listed on the abscissa. Genotypes 6 and 11 are low risk, and other LR indicates other
low-risk genotypes. Genotypes 16, 31, 33, 52, 53, and 58 are high risk, and other HR indicates other high-risk genotypes. The percentage
indicates the prevalence of each genotype within the total HPV genotypes in the HPV-positive population.
and 35% of HPV-negative subjects; 𝑃 = 0.0001) and
more frequently infected through sexual routes (homo- and
heterosexual intercourses accounted for 89%ofHPV-positive
cases versus 68% of HPV-negative cases; 𝑃 = 0.0001).
HPV-coinfected individuals were at a less advanced stage of
HIV disease than HPV-negative ones, as documented by the
shorter duration of HIV infection (median, IQR: 68 months,
29–169 versus 120 months, 39–181; 𝑃 = 0.028) and higher
nadir CD4 cell counts (median, IQR: 271 cells/mmc, 157–392
in HPV positive versus 209 cells/mmc, 139–287; 𝑃 = 0.028).
Current HIV RNA copy levels were higher in HPV-positive
subjects (median, IQR HIV RNA log10 copies/mL: 1.77, 1.59–
3.25 versus 1.59, 1.59–1.79; 𝑃 = 0.0002). Atypical cytology was
diagnosed in 18/76 (23.7%)HPV-negative and 99/201 (49.2%)
HPV-positive subjects (𝑃 = 0.0001) (Table 1).
Amongmales completing the questionnaire, havingmore
than 25 sexual partners, anal and oral intercourses were more
frequent in HPV-positive individuals than HPV-negative
ones. Among women, those with HPV cervical infection had
a higher occurrence of other STDs (Table 2).
3.3. Representation of HPV Genotypes at Anal, Cervical, and
Oral Sites. Theprevalence of differentHPVgenotypes at anal,
cervical, and oral sites is shown in Figure 1. HR genotypes
16 and 18 were detected in 27% and 19% of males and 18%
and 3% of females, respectively.The other frequently detected
genotypes were genotype 6 (accounting for 26% of HPV-
positive men and 16% of women), genotype 58 (in 23% of
men), and genotype 52 (in 10% of women). HPV 16 was
detected in 36%of those individuals found to beHPVpositive
at the oral site.
Overall, men were more likely to harbor genotypes 11
(16% versus 5.4%; 𝑃 = 0.049), 18 (19.45 versus 3.6%; 𝑃 =
0.005), and 58 (23.6% versus 7.2%; 𝑃 = 0.009), whereas there
were no differences in the distribution of other LR and HR
genotypes according to gender.
Up to 37% of men and 20% of women showed multiple
genotypes. Patients with HR-HPV more often harbored
multiple HPV strains compared with those with LR-HPV
(78/144 multiple in HR versus 7/48 in LR; 𝑃 = 0.0001).
3.4. Prevalence and Predictors of Atypical Cytology. Data on
the occurrence of atypical cytology, which were defined as
ASC-US, ASC-H, LSILs, and HSILs, and related variables
were examined in anal (men) and cervical (women) speci-
mens. A total of 7/180 anal specimens (3.8%) and 3/97 (3%)
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Table 3: Univariate and multivariate logistic regressions: factors associated with anal (a) and cervical (b) atypical cytologies.
(a) Factors associated with anal atypical cytology
Univariate Multivariate
OR 95%CI 𝑃 AOR 95%CI 𝑃
Age (each year more) 0.953 0.923–0.984 0.003 0.964 0.928–1.002 0.065
Exposure categories MSM (versus no MSM) 4.046 1.883–8.696 0.0001 2.200 0.892–5.426 0.087
CDC C (yes versus no) 0.674 0.296–1.537 0.348 0.489 0.135–1.775 0.277
HAART (versus naive) 0.440 0.219–0.881 0.020 0.549 0.195–1.542 0.255
Nadir CD4+ T cells (each unit more) 1.000 0.998–1.002 0.945 0.999 0.996–1.001 0.355
HPV infection
HPV negative Ref Ref
LR versus HPV negative 2.731 0.973–8.257 0.075 2.830 2.222–17.036 0.139
HR versus HPV negative 5.233 2.078–13.175 0.0001 3.479 3.543–20.467 0.039
MSM: men who have sex with men; CDC C: AIDS classification according to Atlanta CDC 1993; HAART: highly active antiretroviral therapy; LR: low-
risk genotypes; HR: high-risk genotypes.
(b) Factors associated with cervical atypical cytology
Univariate Multivariate
OR 95%CI 𝑃 AOR 95%CI 𝑃
Age (each year more) 1.000 0.954–1.048 0.992 0.975 0.907–1.047 0.484
Exposure categories
Heterosexual (versus others) 4.046 1.883–8.696 0.0001 3.332 0.782–14.200 0.104
CDC C (yes versus no) 1.315 0.470–3.679 0.502 2.219 0.445–11.066 0.331
HAART (versus naive) 0.556 0.130–2.383 0.429 0.298 0.030–2.941 0.300
Nadir CD4+ T cells (each unit more) 1.002 0.998–1.005 0.367 1.000 0.996–1.004 0.990
HPV infection
HPV negative Ref Ref
LR versus HPV negative 10.800 2.452–47.568 0.002 17.999 2.748–117.9 0.003
HR versus HPV negative 18.857 4.864–73.109 0.0001 26.863 5.195–138.622 0.0001
CDC C: AIDS classification according to Atlanta CDC 1993; HAART: highly active antiretroviral therapy; LR: low-risk genotypes; HR: high-risk
genotypes.
cervical specimens were unsatisfactory for cytologic classifi-
cation and were excluded from the analyses.
No abnormal cytology was found at the oral site. At the
anal site, a total of 83 patients (47%) showed atypical cytology;
11 patients (6%of total) hadHSILs, 62 (35%) had LSILs, and 10
(5%) hadASC-US.A total of 76/83menwith atypical cytology
(91.5%) were HPV positive, and 63 (76%) harbored HR-HPV
strains. HR-HPV was more frequently detected in men with
more severe dysplasia (HR-HPV: 91% among 11 subjects with
HSILs, 79% among 62 with LSILs, 60% among 10 with ASC-
US, and 53% among 92 with normal cytology; 𝑃 = 0.0002).
Two variables were associated with a higher risk of atypical
cytology in a univariate analysis: being infected through the
homosexual route (odds ratio (OR): 4.05; 95%CI: 1.88–8.69)
and harboring HR-HPV (OR: 5.23; 95%CI: 2.08–13.17 versus
HPV negative). Advanced age (OR: 0.95, 95%CI: 0.92–0.98
for each year older) and being on HAART (OR: 0.44, 95%CI:
0.22–0.88 versus HAART naı¨ve) were associated with a lower
risk. After controlling for demographic and HIV-related
factors (age, exposure categories for HIV infection, CDC
stage C, HAART, CD4+ T-cell Nadir count, and presence of
HPV infection), only subjects harboring HR-HPV remained
significantly at risk for atypical cytology comparedwithHPV-
negative individuals (adjusted odds ratio (AOR): 3.48; 95%CI:
3.54–20.47) (Table 3(a)).
Regarding cervical findings, 34 (37%) women showed
abnormal cervical cytology (13 had ASC-US, 1 had ASC-H,
15 had LSILs, 4 had HSILs, and 1 had a diagnosis of in situ
squamous cell cancer). Of these 34 women, 29 (85%) were
HPV positive, and 20 (59%) harbored HR-HPV genotypes.
HR-HPV was detected more frequently in women with more
severe atypical cytology (HR-HPV: 100% in women with
HSILs, 60% in patients with LSILs, 69% in patients with
ASCUS, and 24%women with normal cytology; 𝑃 = 0.0001).
In the univariate model, women infected via the sexual route
were more likely to have atypical cytology (OR: 4.05, 95%
CI: 1.88–8.70 versus no heterosexual infection); no other
demographic or clinical characteristics were associated with
occurrence of atypical cytology. The detection of both LR-
HPV and HR-HPV was associated with atypical cytology
(OR: 10.80, 95%CI: 2.45–47.57 and OR: 18.86, 95%CI: 4.86–
73.11, resp., versus HPV negative). In the multivariate model,
only the presence of either LR-HPV or HR-HPV was con-
firmed to be associated with atypical cytology (OR: 18.00,
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95%CI: 2.75–117.9 and OR: 26.86, 95%CI: 5.19–138.62, resp.,
versus HPV negative) (Table 3(b)).
Overall, men showed a nonstatistically higher risk of SILs
comparedwithwomen (83 out of 180 versus 34 out of 97, resp.,
𝑃 = 0.09).
4. Discussion
In this study, we analyzed the contemporary prevalence of
HPV in both sexes at different sites (genital and oral) in
a population of HIV-positive individuals in a high-income
country.
The overall prevalence of HPV infection in our cohort
was 72.6% (including the anal site in men and cervical site
in women); HPV was more frequent in men than in women
(81% versus 58%), and oral localization was detected in up to
20% of individuals.
Our results are consistent with those of previous studies
conducted in HIV-positive populations, in which the preva-
lence rates of HPV infection were 48%–76.9% [19, 20] in
women and 60%–89% [21, 22] in men. Moreover, among
men, as widely described in the literature [13, 23], HPV
infection at anal site is more frequent in men who have
sex with men compared to those with other risk factors for
HIV. Data from the literature show that HIV-positive MSM
displays a 60-fold higher risk than heterosexual men for the
development of anal cancer [24].
As expected, these prevalence rates are higher than those
observed in the general population [25–27]. Many factors
have been proposed to explain the high HPV prevalence
in HIV-positive subjects. HIV infection could lead to an
increased risk of reactivation of latent infections, and the
persistence of HPV infection could be due to immune system
dysregulation [28]. In addition, the higherHPVprevalence in
HIV-positive population could reflect more active screening
procedures for HPV in comparison to HIV-negative subjects;
the policy of active screening for different diseases in HIV
positive population is consistent with the evidence of being
at risk of several infectious conditions because of immunede-
pression. Moreover, recent studies have shown that infection
with oncogenic HPV genotypes could multiply the risk of
acquiring HIV [29]. In fact, in one recent study, cervicovagi-
nal HPV infection with HR genotypes was associated with an
increased risk of HIV acquisition in women [30].
The estimates of oral HPV prevalence in the literature are
highly variable [31], and it is difficult to discern whether such
variability reflects methodological or population differences.
The 20% prevalence of oral HPV infection identified in our
study is similar to previous data on HIV-infected subjects [6,
21]. The finding of 7 cases (3.5% of the total) with HPV infec-
tion only at the oral site might reflect oral sexual behavior,
which should be taken into account in epidemiological and
clinical studies, even if transmission route of HPV infection
is still unclear and other route than sexual are possible.
In terms of viral genotypes, it is interesting to note that
no concordance in HPV genotype was found in our cohort in
concomitant infections at both oral and genital sites, which
occurred in 38.8% of HPV-positive individuals, and this
result is consistent with previous studies [20, 21]. Different
susceptibilities to HPV infection of the oral and genital
mucosae might explain the differences in HPV genotype
distribution [32].
Regarding the immunovirological profile of our cohort
according to HPV serostatus, we observed that HPV-coin-
fected individuals showed higher median CD4 T-cell counts
compared with HPV-negative subjects. These findings are in
contrast with other studies [21] and might reflect a selection
bias because the majority of subjects that we screened were
“well-being” patients, that is, with better immunological
status and without severe comorbidities. The association
between higher viral load and HPV infection is in line with a
previous study by Strickler et al., which confirmed that high
HIV viral load was strongly associated with the detection of
HPV in women showing either a high (>500 cells per mm3)
or moderate (200–500 cells per mm3) CD4 T-cell count but
not in women with a low CD4 T-cell count [33]. It could be
suggested that nonadherent individuals with a highHIV viral
load have more risky sexual habits, leading to an increased
likelihood of acquiring HPV.
We did not find any associations between HAART usage
and HPV infection. Data regarding the impact of HAART on
HPV infection and HPV-related cervical abnormalities are
inconsistent or controversial [9, 34]. The lack of association
between HAART and HPV in our cohort is consistent with
evidence that the incidence of HPV-related malignancies in
HIV-infected subjects has not declined with the introduction
of potent antiretroviral therapy [9, 35].
High-risk HPV genotypes are associated with the devel-
opment of cancer [36].Globally, theHR-HPVanal prevalence
in our cohort is lower than the data reported by Conley et
al. [22] (possibly because we selected asymptomatic patients)
and similar to that reported in a recent study by Parisi
et al. [21] conducted on HIV-infected patients from the same
geographic area (i.e., Northern Italy).
Regarding cytological data, only 3% of the total specimen
was not appropriate for diagnoses; this percentage is very low
and could not affect the results, in our opinion. Concerning
anal dysplasia, SILs were diagnosed in 47% of men; our
results are in line with those of previous reports showing a
34%–71% prevalence of abnormal anal cytology [31, 37, 38].
The univariate predictors of SILs among men were MSM,
younger age, and infection with HR-HPV; HAART showed
a protective role in SIL development. In the multivariate
model, only HR-HPV infection was confirmed to be signif-
icantly associated with dysplasia. Interestingly, a recent study
confirmed the lower prevalence of HPV infection and anal
SILs in heterosexual men compared with MSM [39]. The
observed association between younger age and dysplasia in
male subjects is not confirmed in other reports on HIV-
negative males [40]. Together with other authors [25, 40],
nevertheless, we speculate that a larger number of sexual
encounters (in younger as well as MSM individuals) might
result in infection with greater number of HPV types, and
this could potentially increase exposure to other unmeasured
risk factors, associated with anal intercourse, and might also
reflect a greater number of mucosal lesions.
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Both LR-HPV and HR-HPV genotypes were associated
with atypical cytology in women of our cohort, with an 85%
prevalence of HPV infection in 59% of cases characterized
by HR genotypes. Data available on Italian women routinely
screened for cervical dysplasia suggest that the prevalence of
HR-HPV and LR-HPV infection is lower than in our cohort
[41].
Notably, up to 53% of men and 24% of women harbor
HR-HPV without any cytologic damage; further studies are
required to better evaluate this population of healthy HR-
HPV carriers. The absence of oral mucosal abnormalities
despite a 20% prevalence of HPV infection at the oral site is
in contrast with recent studies inwhichHIV-positive individ-
uals more frequently displayed an oral mucosal abnormality
[6] than the general population. In fact, HPV is etiologically
associated with a subset of head and neck squamous cell
carcinomas (HNSCCs) [42, 43].The absence of oral dysplasia
in our cohort might be explained by different methods of
collecting mucosal material (cytobrushing instead of biopsy)
or by the site of collection (oral cavity versus tonsillar
epithelium). Even if it must be said that one of the limits of
the present study is represented by the modest sample size,
which might affect the generalizability of our results, we can
draw several conclusions.
The main findings from this cohort study are the high
prevalence of HPV and high-risk HPV genotypes in our
cohort of HIV-positive men and women who are asymp-
tomatic for genital distress. Of major concern is that almost
half of the subjects suffer from genital or anal dysplasia with
different degrees of severity.
The long-term followup of subjects with dysplastic lesions
will clarify their possible evolution in the HIV setting. On
the basis of these results, we suggest mandatory screening
for both HPV and related lesions in all HIV-positive subjects
and the possible implementation of vaccination studies and
programs in HIV-positive/HPV-negative patients.
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